SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of HilleVax, Inc. - HLVX

Core Viewpoint - HilleVax, Inc. is under investigation for potential securities fraud and unlawful business practices following the failure of its clinical trial results, which led to a significant drop in its stock price [5][6][3]. Group 1: Company Overview - HilleVax, Inc. is a publicly traded company on NASDAQ under the ticker HLVX [1]. - The company recently announced topline data from its Phase 2b clinical trial, NEST-IN1, which aimed to evaluate the efficacy of its product HIL-214 in infants [6]. Group 2: Clinical Trial Results - The NEST-IN1 trial did not meet its primary endpoint of efficacy against moderate or severe acute gastroenteritis events caused by specific norovirus genotypes [6]. - No clinical benefit was observed across secondary endpoints in the trial [6]. Group 3: Stock Market Reaction - Following the announcement of the trial results, HilleVax's stock price plummeted by $12.42 per share, representing an 88.3% decrease, closing at $1.64 per share on July 8, 2024 [3]. Group 4: Legal Investigation - Pomerantz LLP is investigating claims on behalf of HilleVax investors regarding potential securities fraud or other unlawful business practices by the company and its officers [5].